Kilitch Drugs (India) Operational Benchmarking
₹249.19-2.76%close, 9 Oct 2026
- Market cap
- ₹871 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹179.42 – ₹336.41
Kilitch Drugs (India) compared with sector peers on revenue, market capitalization, valuation, and return metrics.
Kilitch Drugs (India) sector benchmarking & peer comparison
Operational and financial KPI comparison against sector peers.
| Company | LTP (₹) | P/E | Market Cap (₹ cr) | Div Yield | Qtr Sales (₹ cr) | ROCE % |
|---|---|---|---|---|---|---|
| Kilitch Drugs (India) Limited | ₹249.19 | 22.5 | 871 | 1.2% | 218 | 14.5% |
| Median (1 Cos) | ₹249.19 | 22.5 | 871 | 1.2% | 218 | 14.5% |
Source: NSE sector index filings and financial statements. Data as of 9 October 2026. How this data is compiled.
Same Data For Peers
- Krishna Institute of Medical Sciences Limited operational benchmarking
- Jubilant Pharmova Limited operational benchmarking
- Krsnaa Diagnostics Limited operational benchmarking
- Jupiter Life Line Hospitals Limited operational benchmarking
- Dr. Lal Path Labs Limited. operational benchmarking
- JHS Svendgaard Laboratories Limited operational benchmarking
Trade Kilitch Drugs (India) With ATS
Track KILITCH live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.